Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Alanine Aminotransferase
75%
Amyotrophic Lateral Sclerosis
25%
Bladder Cancer
27%
Breast Cancer
50%
Clinical Feature
25%
Cohort Analysis
33%
Colon Carcinoma
25%
COVID-19
25%
Diseases
47%
Durvalumab
25%
Enfortumab Vedotin
33%
Erdafitinib
50%
Estrogen Receptor
25%
Fibroblast Growth Factor Receptor 3
30%
Forced Vital Capacity
25%
Frailty
55%
Genetic Transfection
25%
Genetics
39%
Health Care Cost
75%
Hepatocellular Carcinoma
50%
Hypofractionated Radiation
25%
Immunotherapy
26%
Kidney Metastasis
50%
Liver Transplantation
30%
Lung Carcinoma
25%
Malignant Neoplasm
28%
Metastatic Carcinoma
31%
Molecular Profiling
25%
Muscle Invasive Bladder Cancer
25%
Neoplasm
26%
Next Generation Sequencing
32%
Nivolumab
25%
Overall Survival
50%
Percutaneous Endoscopic Gastrostomy
25%
Phase II Trials
25%
Prostate Cancer
52%
Radiation Therapy
55%
Real-World Data
29%
Rectum Cancer
25%
Respiratory Failure
25%
Retrospective Study
58%
Risk Stratification
28%
Salivary Gland Neoplasm
25%
Sarcopenia
57%
Squamous Cell Carcinoma
30%
Stereotactic Body Radiation Therapy
25%
Thyroiditis
25%
Transitional Cell Carcinoma
100%
Treatment Outcome
29%
Urinary Tract
25%
Keyphrases
Adenomatous Polyposis Coli
25%
Alanine Aminotransferase
50%
Breast Cancer
26%
Cancer Patients
31%
Cancer Survivors
25%
Clinical Benefit
33%
Confidence Interval
33%
DNA Damage Response
25%
Early Breast Cancer
75%
Erdafitinib
50%
Financial Impact
50%
Fractionation Scheme
30%
Frailty
34%
Germline
25%
Hazard Ratio
28%
Hepatocellular Carcinoma
25%
Human Epidermal Growth Factor Receptor 2 (HER2)
50%
Hypofractionated Radiation
25%
Immune Checkpoint Blockade
31%
Improved Survival
28%
Metastatic Renal Cell Carcinoma (mRCC)
50%
Metastatic Urothelial Carcinoma
32%
Microsatellite Instability-high (MSI-H)
30%
Moderate Hypofractionation
25%
Multicenter Cohort Study
28%
Next-generation Sequencing
34%
Nivolumab
50%
Oncotype DX
28%
Overall Survival
49%
Pathological Features
31%
Pembrolizumab
26%
Percutaneous Endoscopic Gastrostomy
25%
Phase II Trial
25%
Poor Risk
28%
Prognostic Factors
25%
Prostate Cancer Survivors
25%
Radiotherapy
42%
Rectal Cancer
25%
Retrospective Analysis
26%
Retrospective Cohort Analysis
25%
Risk Stratification
28%
Sarcopenia
37%
Short-term Survival
28%
Squamous Cell Carcinoma (SqCC)
31%
Treatment Decisions
28%
Treatment Outcome
29%
Tumor
25%
United States
55%
Urothelial Carcinoma
50%
World Data
29%